ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

IL-6 antibody from Regeneron and Sanofi shows no COVID-19 benefit

by Ryan Cross
May 2, 2020 | APPEARED IN VOLUME 98, ISSUE 17

 

Regeneron and Sanofi posted disappointing results from a Phase II trial testing their arthritis drug Kevzara in people hospitalized with COVID-19. Kevzara is an antibody that binds and blocks the IL-6 receptor. Although the drug lowered IL-6 levels, an action that may slow immune system flaring in COVID-19, the companies found no benefit compared with a placebo. A Phase III trial of the drug will be amended to include only critical patients and will administer only a high dose of Kevzara or a placebo.

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment